Personal tools

Coexpression cluster:C212

From FANTOM5_SSTAR

Revision as of 13:48, 26 November 2012 by Autoedit (talk | contribs)
Jump to: navigation, search


Full id: C212_chronic_acute_Whole_Reticulocytes_leukemia_blood_CD34



Phase1 CAGE Peaks

Hg19::chr11:129815255..129815259,-p@chr11:129815255..129815259
-
Hg19::chr11:36119803..36119812,+p6@LDLRAD3
Hg19::chr11:36119821..36119838,+p3@LDLRAD3
Hg19::chr11:36119843..36119865,+p2@LDLRAD3
Hg19::chr11:36119875..36119897,+p4@LDLRAD3
Hg19::chr11:36119908..36119916,+p7@LDLRAD3
Hg19::chr11:59875891..59875903,-p@chr11:59875891..59875903
-
Hg19::chr11:66469231..66469245,-p@chr11:66469231..66469245
-
Hg19::chr11:66469256..66469259,-p@chr11:66469256..66469259
-
Hg19::chr11:66469260..66469272,-p@chr11:66469260..66469272
-
Hg19::chr13:109281940..109281948,+p11@MYO16
Hg19::chr13:109281953..109281967,+p1@MYO16
Hg19::chr13:109281972..109281975,+p16@MYO16
Hg19::chr13:109281990..109282005,+p2@MYO16
Hg19::chr13:109282019..109282027,+p9@MYO16
Hg19::chr13:114770418..114770438,-p@chr13:114770418..114770438
-
Hg19::chr13:52568084..52568091,-p@chr13:52568084..52568091
-
Hg19::chr14:81894113..81894122,-p5@STON2
Hg19::chr16:2007750..2007753,-p@chr16:2007750..2007753
-
Hg19::chr17:42466942..42466947,-p6@ITGA2B
Hg19::chr18:24283586..24283611,-p1@LOC728606
Hg19::chr18:24283637..24283652,-p2@LOC728606
Hg19::chr19:16011113..16011119,+p@chr19:16011113..16011119
+
Hg19::chr1:147144518..147144523,+p@chr1:147144518..147144523
+
Hg19::chr1:182750217..182750222,-p@chr1:182750217..182750222
-
Hg19::chr1:236205360..236205375,-p@chr1:236205360..236205375
-
Hg19::chr1:246588665..246588670,+p@chr1:246588665..246588670
+
Hg19::chr20:11562510..11562525,-p@chr20:11562510..11562525
-
Hg19::chr20:40344270..40344278,-p@chr20:40344270..40344278
-
Hg19::chr21:16125888..16125904,-p2@ENST00000454128
Hg19::chr22:48134043..48134048,+p@chr22:48134043..48134048
+
Hg19::chr2:159992199..159992211,+p9@TANC1
Hg19::chr2:159994630..159994641,+p@chr2:159994630..159994641
+
Hg19::chr2:190448096..190448099,-p15@SLC40A1
Hg19::chr2:190448106..190448113,-p14@SLC40A1
Hg19::chr2:190448118..190448135,-p4@SLC40A1
Hg19::chr2:209436695..209436715,+p@chr2:209436695..209436715
+
Hg19::chr4:101801270..101801292,-p8@EMCN
Hg19::chr4:103266004..103266021,-p8@SLC39A8
Hg19::chr4:139694701..139694704,+p1@ENST00000502606
Hg19::chr4:139694723..139694753,+p1@ENST00000513400
Hg19::chr4:158656484..158656489,+p@chr4:158656484..158656489
+
Hg19::chr5:134812596..134812620,+p@chr5:134812596..134812620
+
Hg19::chr5:3778511..3778555,+p@chr5:3778511..3778555
+
Hg19::chr5:3784749..3784775,+p@chr5:3784749..3784775
+
Hg19::chr6:124401262..124401310,+p@chr6:124401262..124401310
+
Hg19::chr6:136687033..136687059,-p@chr6:136687033..136687059
-
Hg19::chr6:156941231..156941245,-p@chr6:156941231..156941245
-
Hg19::chr6:16317123..16317126,+p@chr6:16317123..16317126
+
Hg19::chr6:83604219..83604223,+p@chr6:83604219..83604223
+
Hg19::chr7:150654775..150654789,-p@chr7:150654775..150654789
-
Hg19::chr7:150657066..150657083,-p@chr7:150657066..150657083
-
Hg19::chr7:150657124..150657149,-p@chr7:150657124..150657149
-
Hg19::chr7:24835099..24835127,-p@chr7:24835099..24835127
-
Hg19::chr8:105683304..105683308,+p@chr8:105683304..105683308
+
Hg19::chr8:141312919..141312935,-p8@TRAPPC9
Hg19::chr8:28402477..28402490,-p@chr8:28402477..28402490
-
Hg19::chr8:50219668..50219674,+p@chr8:50219668..50219674
+
Hg19::chr8:86240792..86240832,+p1@CU693313
Hg19::chr8:86245780..86245790,-p@chr8:86245780..86245790
-
Hg19::chr8:86290333..86290348,-p1@CA1
Hg19::chr8:91233711..91233743,+p1@ENST00000517400
p1@ENST00000523283
Hg19::chr8:91233744..91233747,+p1@ENST00000524361
Hg19::chr8:91233750..91233766,+p1@ENST00000523406
Hg19::chr8:91233779..91233788,+p3@ENST00000523406
Hg19::chr8:91233817..91233828,+p2@ENST00000523406
Hg19::chr8:91411865..91411868,+p@chr8:91411865..91411868
+
Hg19::chrX:113302371..113302387,-p@chrX:113302371..113302387
-
Hg19::chrX:135866631..135866640,+p@chrX:135866631..135866640
+
Hg19::chrX:81069119..81069129,+p@chrX:81069119..81069129
+


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data


No results for this coexpression

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data


No GOStat results

Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br><br>disease_data<br>


Cell Type
Ontology termp-valuen
myeloid cell1.03e-09108
common myeloid progenitor1.03e-09108
Disease
Ontology termp-valuen
chronic myeloid leukemia9.91e-411
myeloid leukemia2.26e-3231
leukemia6.58e-2639
chronic leukemia7.35e-218
hematologic cancer5.31e-2051
immune system cancer5.31e-2051
organ system cancer8.63e-08137


Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data


Novel motifs



JASPAR motifs

Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}



ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data


(#promoters = Number of promoters in this coexpression cluster that have ChIP signal of the TF)

TF#promotersEnrichmentp-valueq-value
GATA1#2623214.068092443140131.80943924759705e-081.30328293503302e-06
GATA2#2624274.915902240085118.77578425512912e-131.23855963759653e-10
REST#5978141.93000574322560.01178303923400240.0429322088529156
SMARCA4#659748.95805161759360.001081382885241040.00763304590103332
TAL1#68862711.52075214701276.25039865498278e-221.72694546330092e-19



Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data